若生智能
Drug Database
DE

desloratadine + pseudoephedrine (Clarinex D / Aerinaze)

✓ Approved

Merck & Co. · HRH1 · 小分子

什么是 desloratadine + pseudoephedrine？

desloratadine + pseudoephedrine 是一种小分子，由Merck & Co.研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名Clarinex D, Aerinaze
公司Merck & Co.
药物类别小分子
分子靶点HRH1
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Merck & Co.

作用机制

分子靶点

desloratadine + pseudoephedrine 作用于 1 个分子靶点：

HRH1histamine receptor H1 (HH1R, H1R)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

desloratadine + pseudoephedrine 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Immune system disordersSeasonal allergy✓ Approved

相关研究文献

PubMedInternational journal of pharmaceutics2026-06-10

Discrimination of crystal polymorphism in active pharmaceutical ingredients using time-domain 1H NMR relaxation combined with multivariate statistical process control.

Yusuke Minamino M, Oishi Takuya T, Hara Akane A, Katsumata Tsunenobu T et al.

This study investigated the feasibility of evaluating crystal polymorphs of active pharmaceutical ingredients (APIs) using 1H NMR relaxation measurements with time-domain NMR (TD-NMR). Desloratadine, linagliptin, and carbamazepine, each exhibiting multiple polymorphic forms, were selected as model APIs. T1 relaxation times were measured, and the results showed that T1 relaxation behavior differed for each crystal form of the APIs. For desloratadine, an amorphous sample was also prepared and evaluated. It was demonstrated that the T1 relaxation time of the amorphous form was shorter than those of the crystal polymorphs, indicating higher molecular mobility. T1 relaxation curves were further analyzed using multivariate statistical process control (MSPC) based on principal component analysis, and Hotelling's T² and Q statistics successfully distinguished different crystalline forms. In the latter part of this study, physical mixtures of crystal polymorphs were tested to evaluate the detection sensitivity of the MSPC approach. The results demonstrated that this method could identify polymorphic admixtures with a detection limit of approximately 5-10%, depending on the API. TD-NMR offers practical advantages, including rapid measurement, minimal sample preparation, and non-destructive analysis using low-field benchtop instruments. These results indicate that TD-NMR combined with MSPC provides a practical at-line method for monitoring crystal polymorphism and detecting polymorphic contamination during pharmaceutical manufacturing.

PMID 42264055
阅读全文 →
PubMedTalanta2026-06-05

First-derivative spectrofluorometric method based on plasmon-enhanced gold nanoparticles for rapid and ultrasensitive determination of loratadine and pseudoephedrine in human plasma and pharmaceutical dosage forms.

Safwat Nardine N, Hassan Marwa M, Magdy Nancy N, El-Kosasy Amira M AM

Loratadine (LOR) and pseudoephedrine (PSE) are widely used in combination for the treatment of seasonal allergies; therefore, the development of sensitive and reliable analytical methods for their simultaneous determination is essential. In this study, highly sensitive first-derivative spectrofluorimetric method was developed for the first time to resolve the severe spectral overlap between LOR and PSE. Sensitivity was further enhanced through the incorporation of gold nanoparticles (AuNPs). LOR and PSE were selectively determined at 459.6 nm and 466.0 nm following excitation at 230.0 nm and 226.0 nm, respectively. Methanol was used as the diluting solvent with a short shaking time of 10 min after AuNPs addition. Under the optimized conditions, the method showed linear ranges of 0.8-3.5 ng/mL and 70.0-400.0 ng/mL, with detection limits of 0.26 ng/mL and 31.75 ng/mL, for LOR, and PSE; respectively. The proposed method was successfully applied for the determination of LOR and PSE in human plasma with a recovery of 99.60 ± 0.61 and 99.00 ± 0.89 and in pharmaceutical dosage forms with a recovery of 99.78 ± 1.18 and 99.83 ± 0.15; respectively.

PMID 42241873
阅读全文 →
PubMedBirth defects research2026-06-02

Differential Effects of Maternal Exposures on Clubfoot Laterality: A Case-Control Study.

Casey Sharon M SM, Hoffman Molly N MN, Werler Martha M MM, Parker Samantha E SE

Clubfoot is a common birth defect that affects one or both feet. Evidence suggests increased risks of clubfoot in offspring associated with maternal medication and cigarette smoking exposure in early pregnancy. We explored whether such associations differed by clubfoot laterality. This case-control study was conducted in Massachusetts, North Carolina, and New York (2007-2011). State birth defects registries reported clubfoot diagnoses among infants aged < 11 months. Controls without birth defects were random samples of infants from the same catchment areas and born in the same year as cases. Mothers were interviewed within 12 months following delivery. Logistic regression estimated odds ratios (OR) and 95% confidence intervals (CI). Our analysis included 643 isolated cases (bilateral N = 321, left N = 180, right N = 142) and 2037 controls. Estimates for cigarette smoking in early pregnancy were elevated for bilateral, left-sided, and right-sided cases, with the greatest effect for > 10 cigarettes per day for bilateral clubfoot (OR 2.42, 95% CI 1.37, 4.28). Acetaminophen, antihistamines, and pseudoephedrine were not associated with increased risk across laterality groups (ORs ranged 0.42 to 1.05). Elevated ORs (1.22 to 1.44) were observed for ibuprofen use for each laterality group. Associations for salicylates and ondansetron use, however, were observed for bilateral cases only (OR 1.82, 95% CI 1.07, 3.09; OR 1.64, 95% CI 0.99, 2.73, respectively). The pattern of associations across laterality varied by risk factor, suggesting a complex pathogenesis of clubfoot laterality. Investigations that can incorporate both genetic and environmental risk factors are needed to understand clubfoot etiologies.

PMID 42226024
阅读全文 →
PubMedPloS one2026-06-01

Study on the pathogenesis of PLXNB1 gene in olfactory dysfunction of allergic rhinitis.

Chen Xinglong X, Zhao Lingqiong L, Luo Wenlong W

Olfactory dysfunction (OD) is a common yet underrecognized symptom of allergic rhinitis (AR). While inflammation contributes to OD, the underlying molecular mechanisms remain unclear. Differential gene expression analysis was conducted using GEO datasets (GSE75011 and GSE43523). OD DEGs were identified and used to construct a protein-protein interaction (PPI) network. Key genes were filtered through LASSO regression and validated through immune infiltration analysis. The biological function of PLXNB1 was further investigated via in vitro human nasal epithelial cell models and an in vivo mouse model of AR. PLXNB1 expression was significantly downregulated in AR patients compared to healthy controls in both training and validation datasets. Immune infiltration analysis revealed a negative correlation between PLXNB1 and pro-inflammatory immune cells. Functional assays showed that PLXNB1 knockdown led to increased expression of inflammatory cytokines (e.g., IL-4, IL-6), likely via activation of the MAPK/p38 signaling pathway. Conversely, overexpression or Desloratadine treatment restored PLXNB1 levels and suppressed inflammation. PLXNB1 is a potential hub gene linking immune dysregulation to olfactory dysfunction in AR. Its downregulation exacerbates inflammation and may impair olfactory function via the MAPK/p38 axis. These findings offer new insights into AR pathogenesis and identify PLXNB1 as a promising target for therapeutic intervention.

PMID 42224190
阅读全文 →
PubMedJournal of infection and public health2026-05-27

Old drugs, new lifelines: An update on drug repurposing against multidrug-resistant Acinetobacter baumannii.

Saany Mohamad Abavi MA, Jahangiri Abolfazl A

Multidrug-resistant (MDR) Acinetobacter baumannii is a WHO priority pathogen that endures in hospitals and complicates care in intensive care units. Drug repositioning offers a faster path to therapies by reusing approved agents with known safety. This review compiles in vitro and in vivo evidences for repurposed candidates against MDR A. baumannii. Repurposing of anticancer drugs displayed bacterial load reduction and enhancement of polymyxin B through membrane permeabilization. Additionally, antiparasitics increased colistin efficacy by altering surface charge. Furthermore, central nervous system (CNS) agents contributed synergy with traditional antibiotics. Anti-inflammatory and other agents also showed promise: diclofenac enhanced colistin killing, desloratadine blocked growth and synergized with meropenem, and auranofin paired with pentamidine achieved bactericidal effects. Translating these signals will require attention to dosing, delivery, and safety, and rigorous clinical trials. In total, repurposing, particularly in rational combinations, could supply near-term options for severe MDR A. baumannii infections.

PMID 42190543
阅读全文 →
PubMedAsia Pacific allergy2026-05-25

Evaluating montelukast-second-generation antihistamine combinations versus monotherapy in allergic rhinitis: A network meta-analysis.

Wandana Angelina A, Tanely Joyceline Chika JC, Sudrajat Robby Malik Chandra RMC, Alexandra Jeanne J et al.

Allergic rhinitis (AR) is an atopic condition affecting over 400 million people worldwide, impairing quality of life and often leading to complications such as asthma and sinusitis. Montelukast, a leukotriene receptor antagonist, is often used in combination with second-generation antihistamines (sgAHs) to enhance symptom control. However, the relative efficacy of different montelukast-sgAH combinations remains unclear. To evaluate and compare the efficacy of montelukast combined with various sgAHs versus montelukast monotherapy in patients with AR. Randomized controlled trials (RCTs) comparing montelukast-sgAH combinations to montelukast alone were identified from 5 electronic databases up to 2025. Outcomes included Total Nasal Symptom Score (TNSS; 0-12), Daytime and Nighttime Nasal Symptom Scores (DNSS, NNSS; 0-3), and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ; 0-6). Risk of bias (RoB) was assessed using Cochrane RoB 2.0. A frequentist network meta-analysis with subgroup analysis and meta-regression was performed using RStudio and Jeffreys's Amazing Statistics Program. Seventeen RCTs involving 2,655 participants were included. For TNSS improvement, montelukast + desloratadine combination is significantly better than monotherapy in adults (mean difference [MD] = -0.92 [-1.15 to -0.69]) and children (MD = -1.95 [-3.46 to -0.44]). Effects on RQLQ and DNSS were inconsistent, while NNSS improved with montelukast-levocetirizine (P = 0.0384). Heterogeneity was high, but most studies showed low risk of bias. No serious adverse events were reported. Montelukast-sgAH combinations may improve symptoms over monotherapy, especially with desloratadine in both adults and children. However, variability across outcomes and high heterogeneity warrant cautious interpretation and further research.

PMID 42182608
阅读全文 →

注册免费账户还可查看另外 2280 篇文献

免费注册查看全部文献 →

了解更多desloratadine + pseudoephedrine